Servier gains certain rights to Taiho's colorectal cancer drug TAS-102

15 June 2015
servier-big

Japanese drugmaker Taiho Pharmaceutical and independent French pharma company Servier have entered into an exclusive license agreement for the development and commercialization of TAS-102 (trifluridine and tipiracil hydrochloride) in Europe and other countries.

Taiho Pharmaceutical, a subsidiary of Otsuka (TYO: 47680) retains the right to develop and commercialize TAS-102 in the USA, Canada, Mexico and Japan/Asia and to manufacture and supply the product. TAS-102 is an oral combination anticancer drug initially developed by Taiho Pharmaceutical for use in the treatment of refractory metastatic colorectal cancer (mCRC).

$130 million upfront payment to Taiho

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical